Glytrin (Glyceryl Trinitrate)

Glytrin is indicated for the acute relief and prevention of angina pectoris episodes in patients with coronary artery disease.

• Treatment of acute angina attacks when rapid symptom relief is required.
• Prophylactic use to reduce the frequency of angina episodes before physical exertion or emotional stress.
• As part of a comprehensive anti‑anginal regimen in patients already receiving long‑acting nitrate therapy.
• Emergency management of chest pain in a clinical setting when intravenous options are not immediately available.
• Adjunctive therapy for patients undergoing diagnostic stress testing that may provoke myocardial ischemia.

The safety profile of Glytrin reflects its pharmacologic action as a nitrate; side effects are related to vasodilation and systemic exposure.

Common

• Headache, often described as throbbing, due to cerebral vasodilation.
• Flushing or warmth in the face and neck.
• Dizziness or light‑headedness, especially when standing quickly.
• Hypotension manifested as a feeling of faintness or reduced blood pressure.

Serious

• Severe hypotension with syncope, requiring immediate medical attention.
• Reflex tachycardia that may worsen myocardial ischemia and increase heart workload.
• Methemoglobinemia, a rare blood disorder causing cyanosis and reduced oxygen delivery.

When prescribing Glytrin, clinicians consider several precautions to minimize adverse events and ensure safe use.

• Assess baseline blood pressure; avoid use in patients with hypotension or severe hypertension.
• Evaluate for recent use of phosphodiesterase‑5 inhibitors, as combined vasodilation can cause dangerous drops in blood pressure.
• Use caution in patients with anemia, increased intracranial pressure, or severe heart failure.
• Advise patients to sit or lie down when taking the sublingual tablet to reduce risk of dizziness.
• Monitor for tolerance development with long‑term nitrate therapy and consider nitrate‑free intervals.
• Pregnant or breastfeeding women should only use Glytrin if the potential benefit outweighs the risk.

Glytrin can interact with other medications that affect vascular tone or nitric‑oxide pathways.

Avoid

• Concomitant use of phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) due to risk of profound hypotension.
• Combined therapy with other nitrate preparations, which may lead to excessive vasodilation.
• Use with potent antihypertensive agents such as intravenous nitroprusside.

Use with caution

• Beta‑blockers, which may mask tachycardia signs of hypotension.
• Calcium channel blockers, especially dihydropyridines, that can enhance blood‑pressure‑lowering effects.
• Alcohol, which may increase dizziness and hypotensive responses.
• Diuretics, particularly loop diuretics, that may exacerbate volume depletion and hypotension.